Market news

Detailed price information for Nvidia Corp (NVDA-Q) from The Globe and Mail including charting and trades.

Shares of medical technology company Teleflex (NYSE:TFX) jumped 4.5% in the afternoon session after BofA Securities upgraded the stock from Neutral to Buy and raised its price target.

(Updated to include previous price target in headline.) Teleflex (TFX) has an average rating of o

Teleflex (TFX) has an average rating of overweight and mean price target of $154.73, according to an

Teleflex board refresh puts governance in focus Teleflex (TFX) has added veteran medical device executive Sean M. Salmon to its Board of Directors. This appointment gives investors a fresh angle on the company’s governance and its long term direction. Teleflex shares have eased in the short term, with the 7 day share price return down 4.94% and the 30 day share price return down 10.31%. The 90 day share price return of 2.34% and 1 year total shareholder return of 2.67% point to only modest...

Looking back on surgical equipment & consumables - specialty stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Teleflex (NYSE:TFX) and its peers.

WAYNE, Pa., September 08, 2026--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026.

WAYNE, Pa., September 04, 2026--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technology is supported by the previously presented BIONETIC-TRA study, an investigator-initiated study with

Teleflex stock has delivered a sharp decline for long term holders over the past five years, yet today the intrinsic value estimate points to a discount while market based multiples suggest the shares are not cheap. That split, combined with the stock’s recent rebound, puts the current Teleflex valuation under closer scrutiny for investors trying to decide what the market is really pricing in. Teleflex has fallen about 63.6% over five years, which means recent gains still sit against a deep...

TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.

Teleflex's Vascular and Surgical segments are generating high-single-digit growth. Find out why TFX stock is a Buy.

Teleflex’s second quarter was marked by revenue and non-GAAP earnings per share above Wall Street expectations, yet the operating margin declined significantly year over year. Management attributed the quarter’s results primarily to strong execution in its Vascular and Surgical businesses, as well as accelerated progress on its strategic transformation plan. CEO Jason Weidman cited robust demand for hemostatic and ligation products but acknowledged that performance in the Interventional segment

In early August 2026, Teleflex Incorporated reported second-quarter results showing higher sales of US$570.33 million but lower net income of US$99.69 million year-on-year, cut its 2026 earnings guidance, completed a US$250 million repurchase of 1,900,000 shares, and affirmed a quarterly US$0.34 dividend payable on September 30, 2026. The mix of revenue growth alongside weaker earnings, extended integration timelines for the Vascular Intervention acquisition, and active balance sheet...

Motley Fool Press Release.

Detailed price information for Teleflex Inc (TFX-N) from The Globe and Mail including charting and trades.

Evaluate Teleflex's (TFX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Detailed price information for Teleflex Inc (TFX-N) from The Globe and Mail including charting and trades.

Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.

Teleflex (TFX) shares moved on Interventional headwinds and the related 2026 revenue guidance revisi